Leo Pharma starts phase III hand eczema trial
Leo Pharma will test the effectivity of its treatment delgocitinib in treating chronic hand eczema in a phase III trial. It has high hopes for the indication.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY CATHERINE BRETT
After a positive phase II study, Leo Pharma has moved onto phase III trials for its eczema treatment delgocitinib. The first patients have been enrolled in the trial.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Sanofi's Dupixent sales grow 45 percent in Q1
For subscribers
.jpg&w=384&q=75)
